Ramesh Mudududdla

Dr. Ramesh Mudududdla

Medicinal chemistry, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ZZZhen Zhang
Zhen Zhang
CLChunrong Li
Chunrong Li
NHNina J. Hawkins
Nina J. Hawkins
RMRamesh Mudududdla
Ramesh Mudududdla
YNYiming Nie
Yiming Nie
WTWeiping Tang
Weiping Tang
Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune responses and cell death pathways, functioning through both its kinase activity and nonenzymatic scaffolding function. The scaffolding function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for cancer treatment. Recent studies have highlighted RIPK1's potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and X-ray radiotherapy (XRT). In this study, we have developed a highly potent and selective RIPK1 degrader. When combined with XRT, the degrader significantly suppressed tumor growth, achieving enhanced therapeutic efficacy without apparent adverse effects. In contrast, the RIPK1 inhibitor showed no notable therapeutic effect. These findings underscore the potential of targeting RIPK1 degradation, specifically its nonenzymatic function, as a novel strategy to augment the effects of radiotherapy.

10 April 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JSJoel L. Syphers
Joel L. Syphers
JWJosephine A. Wright
Josephine A. Wright
SLShen Liu
Shen Liu
YGYi Sing Gee
Yi Sing Gee
FGFan Gao
Fan Gao
JBJonathan Bayldon Baell
Jonathan Bayldon Baell

18 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Heba Abdellah AliHeba Abdellah Ali
Heba Abdellah Ali
RMRamesh Mudududdla
Ramesh Mudududdla
GCGlen P. Carter
Glen P. Carter
JBJonathan Bayldon Baell
Jonathan Bayldon Baell
Antiretrovirals (ARVs) are a highly effective therapy for treatment and prevention of HIV infection, when administered as prescribed. However, adherence to lifelong ARV regimens poses a considerable challenge and places HIV patients at risk. Long-acting ARV injections may improve patient adherence as well as maintaining long-term continuous drug exposure, resulting in improved pharmacodynamics. In the present work, we explored the aminoalkoxycarbonyloxymethyl (amino-AOCOM) ether prodrug concept as a potential approach to long-acting ARV injections. As a proof of concept, we synthesised model compounds containing the 4-carboxy-2-methyl Tokyo Green (CTG) fluorophore and assessed their stability under pH and temperature conditions that mimic those found in the subcutaneous (SC) tissue. Among them, probe 21 displayed very slow fluorophore release under SC-like conditions (98% of the fluorophore released over 15 d). Compound 25, a prodrug of the ARV agent raltegravir (RAL), was subsequently prepared and evaluated using the same conditions. This compound showed an excellent in vitro release profile, with a half-life (t½) of 19.3 d and 82% of RAL released over 45 d. In mice, 25 extended the half-life of unmodified RAL by 4.2-fold (t½ = 3.18 h), providing initial proof of concept of the ability of amino-AOCOM prodrugs to extend drug lifetimes in vivo. Although this effect was not as pronounced as seen in vitro—presumably due to enzymatic degradation and rapid clearance of the prodrug in vivo—the present results nevertheless pave the way for development of more metabolically stable prodrugs, to facilitate long-acting delivery of ARVs.

16 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Heba Abdellah AliHeba Abdellah Ali
Heba Abdellah Ali
RMRamesh Mudududdla
Ramesh Mudududdla
GCGlen P. Carter
Glen P. Carter
JBJonathan Bayldon Baell
Jonathan Bayldon Baell
Drug targeting is necessary to deliver drugs to a specific site of action at a rate dictated by therapeutic requirements. The pharmacological action of a drug can thereby be optimised while minimising adverse effects. Numerous colonic drug delivery systems have been developed to avoid such undesirable side effects; however, these systems lack site specificity, leaving room for further improvement. The objective of the present study was to explore the potential of amino-alkoxycarbonyloxymethyl (amino-AOCOM) ether prodrugs as a general approach for future colonic delivery. To circumvent inter- and intra-subject variabilities in enzyme activities, these prodrugs do not rely on enzymes but rather are activated via a pH-triggered intramolecular cyclisation–elimination reaction. As proof of concept, model compounds were synthesised and evaluated under various pH conditions, simulating various regions of the gastrointestinal tract (GIT). Probe 15 demonstrated excellent stability under simulated stomach- and duodenum-like conditions and protected 60% of the payload in a small intestine-like environment. Moreover, 15 displayed sustained release at colonic pH, delivering >90% of the payload over 38 h. Mesalamine (Msl) prodrugs 21 and 22 were also synthesised and showed better stability than probe 15 in the simulated upper GIT but relatively slower release at colonic pH (61–68% of Msl over 48 h). For both prodrugs, the extent of release was comparable to that of the commercial product Asacol. This study provides initial proof of concept regarding the use of a cyclisation-activated prodrug for colon delivery and suggests that release characteristics still vary on a case-by-case basis.

6 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
ZZZhen Zhang
Zhen Zhang
CLChunrong Li
Chunrong Li
NHNina Hawkins
Nina Hawkins
RMRamesh Mudududdla
Ramesh Mudududdla
YNYiming Nie
Yiming Nie
WTWeiping Tang
Weiping Tang
Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune re-sponses and cell death pathways, functioning through both its catalytic kinase activity and non-catalytic scaffold function. The scaffold function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for enhancing cancer immunotherapy. Recent studies have highlighted RIPK1’s potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and radio-therapy. In this study, we have developed a highly potent and selective RIPK1 degrader. Our degrader demonstrated signifi-cant tumor growth suppression when combined with X-ray radiotherapy (XRT), achieving enhanced therapeutic efficacy without adverse effects on body weight. These findings underscore the potential of RIPK1 degradation as a novel approach to augment radiotherapy and advance cancer immunotherapy strategies.

25 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
DCDeqin Cai
Deqin Cai
CLChunrong Li
Chunrong Li
MIMalick Bio Idrissou
Malick Bio Idrissou
NHNina Hawkins
Nina Hawkins
RMRamesh Mudududdla
Ramesh Mudududdla
WTWeiping Tang
Weiping Tang
Molecular glue degraders and PROTACs (proteolysis targeting chimeras) are promising therapeutic modalities by hijacking ubiquitin-proteasome pathway to degrade cellular proteins of interests (POIs). However, their clinical applications are often constrained by on-target, off-tissue toxicity. In this study, we present a prostate cancer-targeting delivery strategy for the development of highly potent and selective BRD4 degraders. The tissue-selective degraders are composed of recently reported highly potent BRD4 intramolecular bivalent molecular glue degraders and ligands of prostate-specific membrane antigen (PSMA). The selective degradation of BRD4 was validated both in vitro and in vivo. The mechanism of action was further confirmed through PSMA inhibitor competition. In vivo, selective degradation was observed starting at a dose as low as 1x10-4 mg/kg. This work established a strategy for PSMA targeted delivery of degraders, expanding their potential for clinical applications.